Phase I/II Study of the Safety, Tolerability, and Efficacy of Stereotactic Body Radiation Therapy (SBRT) Combined With Concurrent and Adjuvant Avelumab for Definitive Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I/II
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Avelumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Nov 2018 Planned End Date changed from 1 Mar 2021 to 1 Oct 2021.
- 13 Nov 2018 Planned primary completion date changed from 1 Mar 2020 to 1 Oct 2020.
- 20 Mar 2017 Status changed from not yet recruiting to recruiting.